title: Targeting and eradicating hepatic cancer cells with a cancer-specific vector carrying the Buforin II gene.
abstract: OBJECTIVE
  The aim of this study was to investigate the suppressive effects of Buforin II on the growth of HepG2 cells. To accomplish this, we created a recombinant plasmid (pSUR-Buforin2) in which the survivin promoter was modified to drive the Buforin II gene.
  
  
  METHODS
  The DNA fragment encoding the Buforin II gene was obtained by gene synthesis and cloned into the pSUR-Luc plasmid behind the survivin promoter. The vector was subsequently transfected into HepG2 and LO2 cells. Cell proliferation was measured by the MTT assay, cell cytotoxicity detected by the LDH assay, and cell apoptosis determined by flow cytometry, DNA ladder assays, and immunoblot analysis.
  
  
  RESULTS
  The pSUR-Buforin2 vector effectively suppressed the proliferation of HepG2 cells. The MTT and LDH assay demonstrated that under control of the survivin promoter, Buforin II was not expressed in LO2 cells, but it was expressed in tumor cells where cell death was also observed. AnnexinV-PI staining, DNA ladder assays, and western blots showed massive apoptosis in HepG2 cells transfected with pSUR-Buforin2.
  
  
  CONCLUSIONS
  pSUR-Buforin2 can significantly inhibit the growth of HepG2 cells, resulting in increased cancer cell apoptosis. Thus, this newly designed plasmid might provide a potent and selective anticancer therapy.
authors.affiliation: 1 Department of Laboratory Medicine, The Second Affiliated Hospital, Nanjing Medical University , Nanjing, People's Republic of China .
authors.forename: Yanyun
authors.initials: Y
authors.lastname: Wang
authors.forename: Lili
authors.initials: L
authors.lastname: Qu
authors.forename: Lailing
authors.initials: L
authors.lastname: Gong
authors.forename: Li
authors.initials: L
authors.lastname: Sun
authors.forename: Rujun
authors.initials: R
authors.lastname: Gong
authors.forename: Jin
authors.initials: J
authors.lastname: Si
mesh_terms: D017209:Apoptosis / Q000235:genetics; D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D048708:Cell Growth Processes / Q000235:genetics; D045744:Cell Line, Tumor; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D056945:Hep G2 Cells; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics; D008113:Liver Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D010957:Plasmids / Q000008:administration & dosage / Q000235:genetics; D011401:Promoter Regions, Genetic; D011506:Proteins / Q000235:genetics* / Q000378:metabolism; D000077022:Survivin; D014162:Transfection
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D011506:Proteins; D000077022:Survivin; C097849:buforin II
references.citation: Cancer Res. 1998 Dec 1;58(23):5315-20
references.pmid: 9850056
references.citation: Curr Opin Investig Drugs. 2008 Dec;9(12):1317-23
references.pmid: 19037838
references.citation: Clin Cancer Res. 2008 Aug 15;14(16):5000-5
references.pmid: 18698017
references.citation: Cell Mol Life Sci. 2011 Mar;68(6):1079-90
references.pmid: 20803231
references.citation: Lancet Oncol. 2009 Nov;10(11):1111-8
references.pmid: 19880065
references.citation: Eur Urol. 2006 Jul;50(1):141-7
references.pmid: 16476519
references.citation: Z Gastroenterol. 2012 Sep;50(9):1018-27
references.pmid: 22965633
references.citation: Hepatogastroenterology. 2012 Jan-Feb;59(113):252-4
references.pmid: 22260835
references.citation: Biochem Biophys Res Commun. 1996 Jan 5;218(1):408-13
references.pmid: 8573171
references.citation: Biochem Biophys Res Commun. 1998 Mar 6;244(1):253-7
references.pmid: 9514864
references.citation: Nat Rev Cancer. 2003 Jan;3(1):46-54
references.pmid: 12509766
references.citation: Oncogene. 1998 Dec 24;17(25):3247-59
references.pmid: 9916987
references.citation: J Biol Chem. 2003 Jan 10;278(2):1310-5
references.pmid: 12417587
references.citation: Oncol Rep. 2005 Sep;14(3):595-9
references.pmid: 16077961
references.citation: Acta Biochim Pol. 2011;58(1):111-7
references.pmid: 21403917
references.citation: Mol Ther. 2010 Jan;18(1):63-74
references.pmid: 19724263
references.citation: Cancer Gene Ther. 2004 Nov;11(11):740-7
references.pmid: 15359286
references.citation: Adv Exp Med Biol. 2012;747:55-73
references.pmid: 22949111
references.citation: N Engl J Med. 2002 Oct 10;347(15):1199-200
references.pmid: 12374882
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Eur J Cancer. 2004 Jul;40(10):1474-84
references.pmid: 15196530
references.citation: CA Cancer J Clin. 2010 Nov-Dec;60(6):376-92
references.pmid: 20959400
references.citation: J Natl Cancer Inst. 2002 Apr 3;94(7):522-8
references.pmid: 11929953
references.citation: Clin Colorectal Cancer. 2012 Sep;11(3):185-90
references.pmid: 22280845
references.citation: Biochemistry. 2000 Jul 25;39(29):8648-54
references.pmid: 10913273
references.citation: Cancer Res. 1995 Nov 15;55(22):5283-7
references.pmid: 7585589
references.citation: Swiss Med Wkly. 2001 Jan 12;131(1-2):4-9
references.pmid: 11205184
references.citation: Cancer Lett. 2008 Nov 18;271(1):47-55
references.pmid: 18617323
references.citation: Cancer. 2008 Jan 15;112(2):250-9
references.pmid: 18041064
references.citation: Nat Med. 1997 Aug;3(8):917-21
references.pmid: 9256286
references.citation: Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16
references.pmid: 15508102
references.citation: Am J Pathol. 1998 Jan;152(1):43-9
references.pmid: 9422522
references.citation: BMC Cancer. 2006 Jan 05;6:3
references.pmid: 16396674